Feixiong Cheng1, Junfei Zhao1, Michaela Fooksa2, Zhongming Zhao3. 1. Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA. 2. Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA Chemical and Physical Biology Program, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. 3. Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, TN 37203, USA Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37212, USA Center for Precision Health, School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA zhongming.zhao@uth.tmc.edu.
Abstract
OBJECTIVE: Development of computational approaches and tools to effectively integrate multidomain data is urgently needed for the development of newly targeted cancer therapeutics. METHODS: We proposed an integrative network-based infrastructure to identify new druggable targets and anticancer indications for existing drugs through targeting significantly mutated genes (SMGs) discovered in the human cancer genomes. The underlying assumption is that a drug would have a high potential for anticancer indication if its up-/down-regulated genes from the Connectivity Map tended to be SMGs or their neighbors in the human protein interaction network. RESULTS: We assembled and curated 693 SMGs in 29 cancer types and found 121 proteins currently targeted by known anticancer or noncancer (repurposed) drugs. We found that the approved or experimental cancer drugs could potentially target these SMGs in 33.3% of the mutated cancer samples, and this number increased to 68.0% by drug repositioning through surveying exome-sequencing data in approximately 5000 normal-tumor pairs from The Cancer Genome Atlas. Furthermore, we identified 284 potential new indications connecting 28 cancer types and 48 existing drugs (adjusted P < .05), with a 66.7% success rate validated by literature data. Several existing drugs (e.g., niclosamide, valproic acid, captopril, and resveratrol) were predicted to have potential indications for multiple cancer types. Finally, we used integrative analysis to showcase a potential mechanism-of-action for resveratrol in breast and lung cancer treatment whereby it targets several SMGs (ARNTL, ASPM, CTTN, EIF4G1, FOXP1, and STIP1). CONCLUSIONS: In summary, we demonstrated that our integrative network-based infrastructure is a promising strategy to identify potential druggable targets and uncover new indications for existing drugs to speed up molecularly targeted cancer therapeutics.
OBJECTIVE: Development of computational approaches and tools to effectively integrate multidomain data is urgently needed for the development of newly targeted cancer therapeutics. METHODS: We proposed an integrative network-based infrastructure to identify new druggable targets and anticancer indications for existing drugs through targeting significantly mutated genes (SMGs) discovered in the human cancer genomes. The underlying assumption is that a drug would have a high potential for anticancer indication if its up-/down-regulated genes from the Connectivity Map tended to be SMGs or their neighbors in the human protein interaction network. RESULTS: We assembled and curated 693 SMGs in 29 cancer types and found 121 proteins currently targeted by known anticancer or noncancer (repurposed) drugs. We found that the approved or experimental cancer drugs could potentially target these SMGs in 33.3% of the mutated cancer samples, and this number increased to 68.0% by drug repositioning through surveying exome-sequencing data in approximately 5000 normal-tumor pairs from The Cancer Genome Atlas. Furthermore, we identified 284 potential new indications connecting 28 cancer types and 48 existing drugs (adjusted P < .05), with a 66.7% success rate validated by literature data. Several existing drugs (e.g., niclosamide, valproic acid, captopril, and resveratrol) were predicted to have potential indications for multiple cancer types. Finally, we used integrative analysis to showcase a potential mechanism-of-action for resveratrol in breast and lung cancer treatment whereby it targets several SMGs (ARNTL, ASPM, CTTN, EIF4G1, FOXP1, and STIP1). CONCLUSIONS: In summary, we demonstrated that our integrative network-based infrastructure is a promising strategy to identify potential druggable targets and uncover new indications for existing drugs to speed up molecularly targeted cancer therapeutics.
Authors: Paul Shannon; Andrew Markiel; Owen Ozier; Nitin S Baliga; Jonathan T Wang; Daniel Ramage; Nada Amin; Benno Schwikowski; Trey Ideker Journal: Genome Res Date: 2003-11 Impact factor: 9.043
Authors: Justin Lamb; Emily D Crawford; David Peck; Joshua W Modell; Irene C Blat; Matthew J Wrobel; Jim Lerner; Jean-Philippe Brunet; Aravind Subramanian; Kenneth N Ross; Michael Reich; Haley Hieronymus; Guo Wei; Scott A Armstrong; Stephen J Haggarty; Paul A Clemons; Ru Wei; Steven A Carr; Eric S Lander; Todd R Golub Journal: Science Date: 2006-09-29 Impact factor: 47.728
Authors: Andrea H Bild; Guang Yao; Jeffrey T Chang; Quanli Wang; Anil Potti; Dawn Chasse; Mary-Beth Joshi; David Harpole; Johnathan M Lancaster; Andrew Berchuck; John A Olson; Jeffrey R Marks; Holly K Dressman; Mike West; Joseph R Nevins Journal: Nature Date: 2005-11-06 Impact factor: 49.962
Authors: Lance D Miller; Johanna Smeds; Joshy George; Vinsensius B Vega; Liza Vergara; Alexander Ploner; Yudi Pawitan; Per Hall; Sigrid Klaar; Edison T Liu; Jonas Bergh Journal: Proc Natl Acad Sci U S A Date: 2005-09-02 Impact factor: 11.205
Authors: Mitch Raponi; Yi Zhang; Jack Yu; Guoan Chen; Grace Lee; Jeremy M G Taylor; James Macdonald; Dafydd Thomas; Christopher Moskaluk; Yixin Wang; David G Beer Journal: Cancer Res Date: 2006-08-01 Impact factor: 12.701
Authors: Oliver H Krämer; Ping Zhu; Heather P Ostendorff; Martin Golebiewski; Jens Tiefenbach; Marvin A Peters; Boris Brill; Bernd Groner; Ingolf Bach; Thorsten Heinzel; Martin Göttlicher Journal: EMBO J Date: 2003-07-01 Impact factor: 11.598
Authors: Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards Journal: N Engl J Med Date: 2002-12-19 Impact factor: 91.245
Authors: Tina Hernandez-Boussard; Michelle Whirl-Carrillo; Joan M Hebert; Li Gong; Ryan Owen; Mei Gong; Winston Gor; Feng Liu; Chuong Truong; Ryan Whaley; Mark Woon; Tina Zhou; Russ B Altman; Teri E Klein Journal: Nucleic Acids Res Date: 2007-11-21 Impact factor: 16.971
Authors: Nansu Zong; Ning Li; Andrew Wen; Victoria Ngo; Yue Yu; Ming Huang; Shaika Chowdhury; Chao Jiang; Sunyang Fu; Richard Weinshilboum; Guoqian Jiang; Lawrence Hunter; Hongfang Liu Journal: Brief Bioinform Date: 2022-07-18 Impact factor: 13.994
Authors: Débora Cabral de Carvalho Corrêa; Indhira Dias Oliveira; Bruna Mascaro Cordeiro; Frederico Adolfo Silva; Maria Teresa de Seixas Alves; Nasjla Saba-Silva; Andrea Maria Capellano; Patrícia Dastoli; Sergio Cavalheiro; Silvia Regina Caminada de Toledo Journal: Childs Nerv Syst Date: 2020-06-26 Impact factor: 1.532